Ranbaxy Laboratories has received tentative approval form the Food & Drug Administration USA for manufacturing and marketing Fluconazole tablets, according to a release issued by the company to the Bombay Stock Exchange on Tuesday.
Fluconazole tablets are therapeutically equivalent to the reference listed drug Diflucan tablets of Pfizer Central Research, the release said.
Diflucan is indicated for the treatment of vaginal candidiasis, oropharyngeal and esophageal candidiasis and cryptococcal meningitis, the release added.